1-Deoxy-1-(methylamino)-D-glucitol. A derivative of sorbitol in which the hydroxyl group in position 1 is replaced by a methylamino group. Often used in conjunction with iodinated organic compounds as contrast medium.
Anti-inflammatory analgesic.
A radiopaque medium used for urography, angiography, venography, and myelography. It is highly viscous and binds to plasma proteins.
Substances that are destructive to protozoans.
A class of compounds of the type R-M, where a C atom is joined directly to any other element except H, C, N, O, F, Cl, Br, I, or At. (Grant & Hackh's Chemical Dictionary, 5th ed)
A metallic element that has the atomic symbol Sb, atomic number 51, and atomic weight 121.75. It is used as a metal alloy and as medicinal and poisonous salts. It is toxic and an irritant to the skin and the mucous membranes.
An endemic disease that is characterized by the development of single or multiple localized lesions on exposed areas of skin that typically ulcerate. The disease has been divided into Old and New World forms. Old World leishmaniasis is separated into three distinct types according to epidemiology and clinical manifestations and is caused by species of the L. tropica and L. aethiopica complexes as well as by species of the L. major genus. New World leishmaniasis, also called American leishmaniasis, occurs in South and Central America and is caused by species of the L. mexicana or L. braziliensis complexes.
A parasitic hemoflagellate of the subgenus Leishmania leishmania that infects man and animals and causes visceral leishmaniasis (LEISHMANIASIS, VISCERAL). Human infections are confined almost entirely to children. This parasite is commonly seen in dogs, other Canidae, and porcupines with humans considered only an accidental host. Transmission is by Phlebotomus sandflies.
A parasitic hemoflagellate of the subgenus Leishmania viannia that infects man and animals and causes mucocutaneous leishmaniasis (LEISHMANIASIS, MUCOCUTANEOUS). Transmission is by Lutzomyia sandflies.
A parasitic hemoflagellate of the subgenus Leishmania viannia that infects man and animals. It causes cutaneous (LEISHMANIASIS, CUTANEOUS), diffuse cutaneous (LEISHMANIASIS, DIFFUSE CUTANEOUS), and mucocutaneous leishmaniasis (LEISHMANIASIS, MUCOCUTANEOUS) depending on the subspecies of this organism. The sandfly, Lutzomyia, is the vector. The Leishmania braziliensis complex includes the subspecies braziliensis and peruviana. Uta, a form of cutaneous leishmaniasis in the New World, is caused by the subspecies peruviana.
A parasitic hemoflagellate of the subgenus Leishmania leishmania that infects man and animals including rodents. The Leishmania mexicana complex causes both cutaneous (LEISHMANIASIS, CUTANEOUS) and diffuse cutaneous leishmaniasis (LEISHMANIASIS, DIFFUSE CUTANEOUS) and includes the subspecies amazonensis, garnhami, mexicana, pifanoi, and venezuelensis. L. m. mexicana causes chiclero ulcer, a form of cutaneous leishmaniasis (LEISHMANIASIS, CUTANEOUS) in the New World. The sandfly, Lutzomyia, appears to be the vector.
A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.
Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.
Bactericidal cationic quaternary ammonium surfactant used as a topical anti-infective agent. It is an ingredient in medicaments, deodorants, mouthwashes, etc., and is used to disinfect apparatus, etc., in the food processing and pharmaceutical industries, in surgery, and also as a preservative. The compound is toxic orally as a result of neuromuscular blockade.
A commonly used x-ray contrast medium. As DIATRIZOATE MEGLUMINE and as Diatrizoate sodium, it is used for gastrointestinal studies, angiography, and urography.
An oligosaccharide antibiotic produced by various STREPTOMYCES.
Tests that demonstrate the relative effectiveness of chemotherapeutic agents against specific parasites.
A contrast medium in diagnostic radiology with properties similar to those of diatrizoic acid. It is used primarily as its sodium and meglumine (IOTHALAMATE MEGLUMINE) salts.
Measure of the number of the PARASITES present in a host organism.
A disease caused by any of a number of species of protozoa in the genus LEISHMANIA. There are four major clinical types of this infection: cutaneous (Old and New World) (LEISHMANIASIS, CUTANEOUS), diffuse cutaneous (LEISHMANIASIS, DIFFUSE CUTANEOUS), mucocutaneous (LEISHMANIASIS, MUCOCUTANEOUS), and visceral (LEISHMANIASIS, VISCERAL).
A versatile contrast medium used for DIAGNOSTIC X-RAY RADIOLOGY.
Radiography of the ventricular system of the brain after injection of air or other contrast medium directly into the cerebral ventricles. It is used also for x-ray computed tomography of the cerebral ventricles.
Antimony complex where the metal may exist in either the pentavalent or trivalent states. The pentavalent gluconate is used in leishmaniasis. The trivalent gluconate is most frequently used in schistosomiasis.
A phospholipid from the platelet membrane that contributes to the blood clotting cascade by forming a phospholipid-protein complex (THROMBOPLASTIN) which serves as a cofactor with FACTOR VIIA to activate FACTOR X in the extrinsic pathway of BLOOD COAGULATION.
A genus of flagellate protozoa comprising several species that are pathogenic for humans. Organisms of this genus have an amastigote and a promastigote stage in their life cycles. As a result of enzymatic studies this single genus has been divided into two subgenera: Leishmania leishmania and Leishmania viannia. Species within the Leishmania leishmania subgenus include: L. aethiopica, L. arabica, L. donovani, L. enrietti, L. gerbilli, L. hertigi, L. infantum, L. major, L. mexicana, and L. tropica. The following species are those that compose the Leishmania viannia subgenus: L. braziliensis, L. guyanensis, L. lainsoni, L. naiffi, and L. shawi.
Quinolines substituted in any position by one or more amino groups.
A disease characterized by the chronic, progressive spread of lesions from New World cutaneous leishmaniasis caused by species of the L. braziliensis complex to the nasal, pharyngeal, and buccal mucosa some time after the appearance of the initial cutaneous lesion. Nasal obstruction and epistaxis are frequent presenting symptoms.
A parasitic hemoflagellate of the subgenus Leishmania leishmania that infects man and rodents. This taxonomic complex includes species which cause a disease called Oriental sore which is a form of cutaneous leishmaniasis (LEISHMANIASIS, CUTANEOUS) of the Old World.
2-, 3-, or 4-Pyridinecarboxylic acids. Pyridine derivatives substituted with a carboxy group at the 2-, 3-, or 4-position. The 3-carboxy derivative (NIACIN) is active as a vitamin.
Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it.
Diseases of domestic and wild horses of the species Equus caballus.
Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.
Substances used to allow enhanced visualization of tissues.
Societies whose membership is limited to pharmacists.
Advanced programs of training to meet certain professional requirements in fields other than medicine or dentistry, e.g., pharmacology, nutrition, nursing, etc.
Books in the field of medicine intended primarily for consultation.
Those persons legally qualified by education and training to engage in the practice of pharmacy.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions.They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.
Diseases of the muscles and their associated ligaments and other connective tissue and of the bones and cartilage viewed collectively.
Services providing pharmaceutic and therapeutic drug information and consultation.
Gadolinium. An element of the rare earth family of metals. It has the atomic symbol Gd, atomic number 64, and atomic weight 157.25. Its oxide is used in the control rods of some nuclear reactors.
The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action.
A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see PENTETIC ACID), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706)
Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.
Compounds formed by the joining of smaller, usually repeating, units linked by covalent bonds. These compounds often form large macromolecules (e.g., BIOPOLYMERS; PLASTICS).
A specialty concerned with the use of x-ray and other forms of radiant energy in the diagnosis and treatment of disease.

Low resting potential and postnatal upregulation of NMDA receptors may cause Cajal-Retzius cell death. (1/478)

Using in situ patch-clamp techniques in rat telencephalic slices, we have followed resting potential (RP) properties and the functional expression of NMDA receptors in neocortical Cajal-Retzius (CR) cells from embryonic day 18 to postnatal day 13, the time around which these cells normally disappear. We find that throughout their lives CR cells have a relatively depolarized RP (approximately -50 mV), which can be made more hyperpolarized (approximately -70 mV) by stimulation of the Na/K pump with intracellular ATP. The NMDA receptors of CR cells are subjected to intense postnatal upregulation, but their similar properties (EC50, Hill number, sensitivity to antagonists, conductance, and kinetics) throughout development suggest that their subunit composition remains relatively homogeneous. The low RP of CR cells is within a range that allows for the relief of NMDA channels from Mg2+ blockade. Our findings are consistent with the hypothesis that CR cells may degenerate and die subsequent to uncontrolled overload of intracellular Ca2+ via NMDA receptor activation by ambient glutamate. In support of this hypothesis we have obtained evidence showing the protection of CR cells via in vivo blockade of NMDA receptors with dizocilpine.  (+info)

Overexpression of the multidrug resistance-associated protein (MRP1) in human heavy metal-selected tumor cells. (2/478)

Cellular and molecular mechanisms involved in the resistance to cytotoxic heavy metals remain largely to be characterized in mammalian cells. To this end, we have analyzed a metal-resistant variant of the human lung cancer GLC4 cell line that we have selected by a step-wise procedure in potassium antimony tartrate. Antimony-selected cells, termed GLC4/Sb30 cells, poorly accumulated antimony through an enhanced cellular efflux of metal, thus suggesting up-regulation of a membrane export system in these cells. Indeed, GLC4/Sb30 cells were found to display a functional overexpression of the multidrug resistance-associated protein MRP1, a drug export pump, as demonstrated by Western blotting, reverse transcriptase-polymerase chain reaction and calcein accumulation assays. Moreover, MK571, a potent inhibitor of MRP1 activity, was found to markedly down-modulate resistance of GLC4/Sb30 cells to antimony and to decrease cellular export of the metal. Taken together, our data support the conclusion that overexpression of functional MRP1 likely represents one major mechanism by which human cells can escape the cytotoxic effects of heavy metals.  (+info)

Value of Western blotting in the clinical follow-up of canine leishmaniasis. (3/478)

Specific serum antibody levels in Leishmania infantum-infected dogs treated with a combination of glucantime and allopurinol were estimated by indirect immunofluorescence and Western blotting. The sensitivity of Western blot was greater than that obtained with immunofluorescence titration. In general, both diagnostic methods concurred with the post-treatment clinical status of the animals. Clinical improvement of successfully treated dogs was related to lower immunofluorescence titers and simpler and/or less reactive immunodetection patterns in Western blotting. The recognition, by infected dogs, of certain low molecular weight antigens, particularly one of approximately 26 kDa, was restricted to pretreatment samples and a single animal in relapse thus apparently constituting an active infection marker.  (+info)

Supraspinal neurotensin-induced antianalgesia in mice is mediated by spinal cholecystokinin. (4/478)

Intracerebral injection of neurotensin into specific brain loci in rats produces hyperalgesia due to the release of cholecystokinin (CCK) in the spinal cord. The present purpose was to show in another species that neurotensin can antagonize the antinociceptive action of morphine through the spinal CCK mechanism in mice. Neurotensin given intracerebroventricularly (i.c.v.) at doses higher than 100 ng produced antinociception in the tail flick test. However, at lower doses between 1 pg to 25 ng, neurotensin antagonized the antinociceptive action of morphine given intrathecally (i.t.), thus demonstrating the antianalgesic activity of neurotensin. The rightward shift in the morphine dose-response curve produced by i.c.v. neurotensin was eliminated by an i.t. pretreatment with CCK8 antibody (5 microl of antiserum solution diluted 1:1000). I.t. administration of lorglumide, a CCK(A)-receptor antagonist (10-1000 ng), and PD135,158, a CCK(B)-receptor antagonist (250-500 ng), also eliminated the antianalgesic action of neurotensin. Thus, the mechanism of the antianalgesic action of neurotensin given i.c.v. involved spinal CCK. This mode of action is similar to that for the antianalgesic action of supraspinal pentobarbital which also involves spinal CCK.  (+info)

Analysis of the behaviour of selected CCKB/gastrin receptor antagonists in radioligand binding assays performed in mouse and rat cerebral cortex. (5/478)

1. The previously described complex behaviour of the CCKB/gastrin receptor antagonist, L-365,260, in radioligand binding assays could be explained by a variable population of two binding sites. We have investigated whether other CCKB/gastrin receptor ligands (PD134,308, PD140,376, YM022 and JB93182) can distinguish between these sites. 2. In the mouse cortex assay, Hill slopes were not different from unity and the ligand pKI values did not differ when either [125I]-BH-CCK-8S or [3H]-PD140,376 was used as label as expected for a single site (G2). 3. In the rat cortex, where previous analysis of replicate (n=48) L-365,260 data indicated the presence of two CCKB/gastrin sites (G1 and G2), the competition data for PD134,308, PD140,376, YM022 and JB93182 could be explained by a homogeneous population of CCKB/gastrin sites because the Hill slope estimates were not significantly different from unity. However, the estimated affinity values for JB93182 and YM022 were significantly higher and that for PD134,308 was significantly lower than those obtained in the mouse cortex when the same radioligand was used. In view of our previous data obtained with L-365,260, the rat cortex data were also interpreted using a two-site model. In this analysis, SR27897 expressed approximately 9 fold, PD134,308 approximately 13 fold and PD140,376 approximately 11 fold selectivity for the G2 site. In contrast, JB93182 expressed approximately 23 fold and YM022 approximately 4 fold selectivity for the G1 site. If the two-site interpretation of the data is valid then, because of its reverse selectivity to L-365,260, JB93182 has been identified as a compound which if radiolabelled could provide a test of this receptor subdivision.  (+info)

Characterization of the binding of a novel radioligand to CCKB/gastrin receptors in membranes from rat cerebral cortex. (6/478)

1. We have investigated the binding of a novel radiolabelled CCKB/gastrin receptor ligand, [3H]-JB93182 (5[[[(1S)-[[(3,5-dicarboxyphenyl)amino]carbonyl]-2-phenylethyla mino]-carbonyl]-6-[[(1-adamantylmethyl) amino]carbonyl]-indole), to sites in rat cortex membranes. 2. The [3H]-JB93182 was 97% radiochemically pure as assessed by reverse-phase HPLC (RP-HPLC) and was not degraded by incubation (150 min) with rat cortex membranes. 3. Saturation analysis indicated that [3H]-JB93182 labelled a homogeneous population of receptors in rat cortex membranes (pKD=9.48+/-0.08, Bmax=3.61+/-0.65 pmol g(-1) tissue, nH=0.97+/-0.02, n=5). The pKD was not significantly different when estimated by association-dissociation analysis (pKD=9.73+/-0.11; n=10). 4. In competition studies, the low affinity of the CCKA receptor antagonists, L-364,718; SR27897 and 2-NAP, suggest that, under the assay conditions employed, [3H]-JB93182 (0.3 nM) does not label CCKA receptors in the rat cortex. 5. The affinity estimates obtained for reference CCKB/gastrin receptor antagonists were indistinguishable from one of the affinity values obtained when a two site model was used to interpret [125I]-BH-CCK8S competition curves obtained in the same tissue (Harper et al., 1999). 6. This study provides further evidence for the existence of two CCKB/gastrin sites in rat cortex. [3H]-JB93182 appears to label selectively sites previously designated as gastrin-G1 and therefore it may be a useful compound for the further discrimination and characterization of these putative receptor subtypes.  (+info)

Differential effects of intrathecally administered morphine and its interaction with cholecystokinin-B antagonist on thermal hyperalgesia following two models of experimental mononeuropathy in the rat. (7/478)

BACKGROUND: Cholecystokinin-B receptor activation has been reported to reduce morphine analgesia. Neuropathic pain is thought to be relatively refractory to opioids. One possible mechanisms for a reduced effect of morphine on neuropathic pain is the induction of cholecystokinin in the spinal cord by nerve injury. The authors evaluated the role of the spinal cholecystokinin-B receptor on morphine analgesia in two rat neuropathic pain models: chronic constriction injury and partial sciatic nerve injury. METHODS: A chronic constriction injury is created by placing four loosely tied ligatures around the right sciatic nerve. A partial sciatic nerve injury was created by tight ligation of one third to one half of the right sciatic nerve. All drugs were injected intrathecally 7 and 11 days after the nerve injury. The effect of the drugs was reflected in the degree of paw withdrawal latency to thermal nociceptive stimulation. The paw withdrawal latencies of injured and uninjured paws were measured 5, 15, 30, and 60 min after the drugs were injected. RESULTS: In the chronic constriction injury model, intrathecal morphine increased the paw withdrawal latencies of injured and uninjured paws. PD135158, a cholecystokinin-B receptor antagonist, potentiated the analgesic effect of morphine on injured and uninjured paws. In the partial sciatic nerve injury model, the effect of morphine on the injured paw was less potent than that on the uninjured paw, and PD135158 potentiated the morphine analgesia in the uninjured paw and had only a minor effect on the morphine analgesia in the injured paw. CONCLUSIONS: The effectiveness of morphine for thermal hyperalgesia after nerve injury depends on the type of nerve injury. The role of the cholecystokinin-B receptor in morphine analgesia in thermal hyperalgesia after nerve injury also depends on the type of nerve injury.  (+info)

Glycine-extended gastrin exerts growth-promoting effects on human colon cancer cells. (8/478)

BACKGROUND: Since human colon cancers often contain significant quantities of progastrin-processing intermediates, we sought to explore the possibility that the biosynthetic precursor of fully processed amidated gastrin, glycine-extended gastrin, may exert trophic effects on human colonic cancer cells. MATERIALS AND METHODS: Binding of radiolabeled glycine-extended and amidated gastrins was assessed on five human cancer cell lines: LoVo, HT 29, HCT 116, Colo 320DM, and T 84. Trophic actions of the peptides were assessed by increases in [3H]thymidine incorporation and cell number. Gastrin expression was determined by northern blot and radioimmunoassay. RESULTS: Amidated gastrin did not bind to or stimulate the growth of any of the five cell lines. In contrast, saturable binding of radiolabeled glycine-extended gastrin was seen on LoVo and HT 29 cells that was not inhibited by amidated gastrin (10(-6) M) nor by a gastrin/CCKB receptor antagonist (PD 134308). Glycine-extended gastrin induced a dose-dependent increase in [3H]thymidine uptake in LoVo (143 +/- 8% versus control at 10(-10) M) and HT 29 (151 +/- 11% versus control at 10(-10) M) cells that was not inhibited by PD 134308 or by a mitogen-activated protein (MAP) or ERK kinase (MEK) inhibitor (PD 98509). Glycine-extended gastrin did stimulate jun-kinase activity in LoVo and HT 29 cells. The two cell lines expressed the gastrin gene at low levels and secreted small amounts of amidated gastrin and glycine-extended gastrin into the media. CONCLUSIONS: Glycine-extended gastrin receptors are present on human colon cancer cells that mediate glycine-extended gastrin's trophic effects via a MEK-independent mechanism. This suggests that glycine-extended gastrin and its novel receptors may play a role in colon cancer cell growth.  (+info)

View more ,We sought to investigate the T1 kinetics of blood and myocardium after three infusion schemes of gadobenate dimeglumine (Gd‐BOPTA) and subsequently compared contrast‐enhanced whole‐heart coronary MRI after a bolus Gd‐BOPTA infusion with nonenhanced coronary MRI at 1.5 T. Blood and myocardium T1 was measured in seven healthy adults, after each underwent three Gd‐BOPTA infusion schemes (bolus: 0.2 mmol/kg at 2 mL/sec, hybrid: 0.1 mmol/kg at 2 mL/sec followed by 0.1 mmol/kg at 0.1 mL/sec, and slow: 0.2 mmol/kg at 0.3 mL/sec). Fourteen additional subjects underwent contrast‐enhanced coronary MRI with an inversion‐recovery steady‐state free precession sequence after bolus Gd‐BOPTA infusion. Images were compared with nonenhanced T2‐prepared steady‐state free precision whole‐heart coronary MRI in signal‐to‐noise ratio, contrast‐to‐noise ratio, depicted vessel length, vessel sharpness, and subjective image quality. Bolus and slow infusion schemes resulted in ...
METHODS: In this blinded randomized crossover study, 20 patients with known myocardial infarction underwent two separate delayed-enhancement MRI examinations after receiving 0.1 mmol/kg gadobenate dimeglumine and 0.2 mmol/kg gadopentetate dimeglumine (random administration). The conspicuity of lesion enhancement 5, 10, and 20 minutes after contrast administration was quantified as relative enhancement ratio (RER).. RESULTS: With either gadolinium-based contrast agent, damaged myocardium had higher signal intensity than normal remote myocardium (RER , 4) on delayed-enhancement MR images, and the blood RER declined over time after contrast administration. The blood RER was not significantly higher for gadobenate dimeglumine than for gadopentetate dimeglumine at 5 and 10 minutes. Nevertheless, there was a larger reduction in blood RER for gadobenate dimeglumine than for gadopentetate dimeglumine between 5 and 10 minutes and between 10 and 20 minutes. The volumes of enhancement were similar for ...
TY - JOUR. T1 - Focal liver lesions. T2 - Evaluation of the efficacy of gadobenate dimeglumine in MR imaging - A multicenter phase III clinical study. AU - Petersein, Jan. AU - Spinazzi, Alberto. AU - Giovagnoni, Andrea. AU - Soyer, Philippe. AU - Terrier, Francois. AU - Lencioni, Riccardo. AU - Bartolozzi, Carlo. AU - Grazioli, Luigi. AU - Chiesa, Antonio. AU - Manfredi, Riccardo. AU - Marano, Pasquale. AU - Van Persijn Van Meerten, Els L.. AU - Bloem, Johannes L.. AU - Petre, Carina. AU - Marchal, Guy. AU - Greco, Alina. AU - McNamara, Michael T.. AU - Heuck, Andreas. AU - Reiser, Maximilian. AU - Laniado, Michael. AU - Claussen, Claus. AU - Daldrup, Heike E.. AU - Rummeny, Ernst. AU - Kirchin, Miles A.. AU - Pirovano, Gianpaolo. AU - Hamm, Bernd. PY - 2000/6. Y1 - 2000/6. N2 - PURPOSE: To evaluate gadobenate dimeglumine (Gd-BOPTA) for dynamic and delayed magnetic resonance (MR)imaging of focal liver lesions. MATERIALS AND METHODS: In 126 of 214 patients, MR imaging was performed before ...
|i|Purpose|/i|. Retrospective comparison between gadofosveset trisodium and gadobenate dimeglumine steady state magnetic resonance angiography (SS-MRA) of the thoracic vasculature at 1.5T using signal-to-noise ratio (SNR) and vessel edge sharpness (ES) as markers of image quality. |i|Materials and Methods|/i|. IRB approval was obtained. Twenty separate patients each underwent SS-MRA using high-resolution 3D ECG-triggered coronal IR-TFE at 1.5T approximately 3-4 minutes following 10 or 15 mL gadofosveset or 20 mL gadobenate. ROIs were placed in the right atrium, left ventricle, left atrium, ascending aorta, descending aorta, and right pulmonary artery to estimate SNR. Vessel ES was estimated as 20-80% rise distances from line intensity profiles in the left pulmonary vein, ascending aorta, and descending aorta. Data were analyzed using nonpaired Students |svg xmlns:xlink=http://www.w3.org/1999/xlink xmlns=http://www.w3.org/2000/svg style=vertical-align:-0.11285pt;width:5.9250002px; id=M1 height=
Gadoterate meglumine(Dotatrem) generic is a gadolinium based contrast agent, prescribed for visualization of brain along with with magnetic resonance imaging (MRI).
Learn about the potential side effects of gadoterate meglumine. Includes common and rare side effects information for consumers and healthcare professionals.
Read the side effects of Gadoterate meglumine as described in the medical literature. In case of any doubt consult your doctor or pharmacist.
GMP grade Meglumine / CAS 6284-40-8/N-Methyl-D-glucamine,US $ 15.9 - 15.9, 6284-40-8, 6284-40-8, N-Methyl-D-glucamine, C7H17NO5.Source from N&R Bio Industries Inc. (Xian) on Alibaba.com.
A comparative study on the efficacy of combination therapy with Omeprazole and low dose systemic Meglumine Antimoniate (Glucantime) and the full dose systemic Meglumine Antimoniate in the treatment of cutaneous ...
RESULTS: One hundred fourteen of 123 enrolled patients successfully underwent both examinations. Final diagnoses were intra-axial tumors, metastases, extra-axial tumors, other tumors, and nontumor (49, 46, 8, 7, and 4 subjects, respectively). Readers 1, 2, and 3 demonstrated preference for gadobenate dimeglumine in 46 (40.7%), 54 (47.4%), and 49 (43.0%) patients, respectively, compared with 6, 7, and 7 patients for gadobutrol (P , .0001, all readers). Highly significant (P , .0001, all readers) preference for gadobenate dimeglumine was demonstrated for all other qualitative end points. Inter-reader agreement was good for all evaluations (K = 0.414 - 0.629). Significantly superior CNR and LBR were determined for gadobenate dimeglumine (P , .019, all readers).. ...
There was no detectable biotransformation of gadobenate ion. Dissociation of gadobenate ion in vivo has been shown to be minimal, with less than 1% of the free chelating agent being recovered alone in feces.. Pharmacokinetics in Special Population Renal Impairment: A single intravenous dose of 0.2 mmol/kg of MultiHance was administered to 20 subjects with impaired renal function (6 men and 3 women with moderate renal impairment [urine creatinine clearance ,30 to ,60 mL/min] and 5 men and 6 women with severe renal impairment [urine creatinine clearance ,10 to ,30 mL/min]). Mean estimates of the elimination half-life were 6.1 ± 3.0 and 9.5 ± 3.1 hours for the moderate and severe renal impairment groups, respectively as compared with 1.0 to 2.0 hours in healthy volunteers. Hemodialysis: A single intravenous dose of 0.2 mmol/kg of MultiHance was administered to 11 subjects (5 males and 6 females) with end-stage renal disease requiring hemodialysis to determine the pharmacokinetics and ...
In recent years, there have been a number of studies comparing different gadolinium chelates for MR imaging of tumors, particularly for MR imaging of intracranial neoplasms. These have included intraindividual studies that compared gadobenate dimeglumine (MultiHance; Bracco, Milan, Italy) with other gadolinium agents1-3 for imaging cerebral tumors, and a study similar to that of Kim et al4 that compared gadobutrol (Gadovist; Bayer Schering Pharma, Berlin, Germany) with gadopentetate dimeglumine (Magnevist; Bayer Schering Pharma) for imaging of cerebral metastasis.5. Studies comparing gadobenate dimeglumine with other gadolinium chelates have demonstrated the superiority of this agent in terms of contrast enhancement and lesion characterization, delineation, extension, and definition of internal structures at 1.5T and 3T. Lesions included were mostly intracranial tumors, with the highest percentage being intraparenchymal gliomas. Although detailed evaluation of different histologic types has yet ...
March 21, 2013 -- Guerbet announced that the U.S. Food and Drug Administration (FDA) has approved Dotarem (gadoterate meglumine), a gadolinium-based contrast agent (GBCA) indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.. Dotarem - which has been commercialized widely throughout the world since 1989 and more than 37 million doses administered[1] - is the only macrocyclic and ionic GBCA. The recommended dose is 0.2 mL/kg (0.1 mmol/kg) body weight (BW). Dotarem injection 0.5 mmol/mL contains 376.9 mg/mL of gadoterate meglumine, and is available in vials and pre?filled syringes.. This approval is a major milestone for Guerbet, which has a proud history of providing safe and effective contrast agents to patients worldwide, said Yves LEpine, CEO of Guerbet Group. ...
GE Healthcares innovative shatterproof polymer +PLUSPAK Pharmacy Bulk Package has been approved by the US FDA for use with its macrocyclic gadolinium
MilliporeSigma, a leading science and technology company, today announced the opening of a facility in Mollet des Vallès, Spain dedicated to the manufacture of meglumine, an FDA-approved excipient for pharmaceuticals and a component of medical imaging contrast media.
Delafloxacin Meglumine reference guide for safe and effective use from the American Society of Health-System Pharmacists (AHFS DI).
Gadolinium chelate that has a similar action and use than gadopentetic acid. At latest update no published data on excretion into breast milk were found. It has been used in the pediatric age. The various contrast media that are gadolinium derivatives and used for explorations with Magnetic Resonance Imaging (MRI) are considered compatible with breastfeeding because they are quickly eliminated (elimination half-life of less than 2 hours). They undergo very little metabolic changes and are virtually non-absorbable orally. They are structurally very similar to each other. Some have been shown to have no or minimal excretion into the milk (ACR 2018 p99, Wang 2012, Rubik 2000, Rofsky 1993). Less than 0.04% of the dose given to the mother ends just going into the milk (ACR 2018 p99, Wang 2012, Rubik 2000, Rofsky 1993). Due to its low oral bioavailability, intestinal absorption should be less than 1% of the dose took by the infant. The maximum dose received by the infant is considered less
Efficacy of topical 5% imiquimod with cryotherapy versus intralesional meglumine antimoniate in the treatment of anthroponotic cutaneous ...
Dotarem Project name: gadoterate meglumine Disease: Central nervous system diagnostic agent Peak sales estimate: North of $205 million Approved: March 21 Company: Guerbet The Scoop: Guerbets...
TY - JOUR. T1 - Enhancement of abdominal structures on MRI at 1.5 and 3 T. T2 - European Radiology. AU - AlObaidy,Mamdoh. AU - Ramalho,Miguel. AU - Velloni,Fernanda. AU - Matos,António P.. AU - Herman,Kevin. AU - Semelka,Richard C.. PY - 2017/4/1. Y1 - 2017/4/1. N2 - Objective: To quantitatively compare the extent of enhancement of abdominal structures on MRI in an intraindividual fashion at 1.5 and 3 T. Methods: HIPAA-compliant, retrospective, longitudinal, intraindividual, crossover study, with waived informed consent, of consecutive individuals scanned at both 1.5 and 3 T closed-bore magnets using gadobenate dimeglumine during different phases of enhancement at tightly controlled arterial phase timing. Quantitative ROI measurements and qualitative sub-phase arterial phase assignments were independently performed by two radiologists. Qualitative discrepancies were resolved by a senior radiologist. Results: Final population included 60 patients [41 female and 19 male; age, 49.35 ± 18.31 years ...
Viral infections affect three to five million patients annually. antiviral treatment, this review provides the verified data around the medicinal plants and related herbal substances ABT 492 meglumine (Delafloxacin meglumine) with antiviral activity, as well as applied strategies for the delivery of these herb extracts and biologically active phytochemicals. Open in a separate windows Graphical Abstract against most viruses, but often are ineffective in patients. Ninety different antiviral brokers available today [3, 4] only treat a selection of viruses; these viruses include HIV (human immunodeficiency computer virus), herpes viruses, including HSV (herpes simplex virus), hCMV (human cytomegalovirus), VZV (varicella zoster computer virus), influenza viruses, and the hepatitis viruses (Fig. ?(Fig.1).1). Currently, there is no approved remedy for many types or viruses, and vaccination is limited to hepatitis A computer virus, mumps, and varicella [2]. In addition, these brokers are often costly ...
WHITEHOUSE STATION, N.J.- Merck & Co., Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved EMEND (fosaprepitant dimeglumine) for Injection, a new intravenous therapy fo...
AASraw ni mtengenezaji wa uzalishaji wa wingi wa Fosaprepitant dimeglumine chini ya udhibiti wa CGMP, na hutoa mauzo ya mtandaoni, kemikali ya synthetic na iliyoboreshwa,
Evaluation of a Possible Synergistic Effect of Meglumine Antimoniate with Paromomycin, Miltefosine or Allopurinol on in Vitro Susceptibility of Leishmania tropica Resistant Isolate.
China Flunixin Injection Exporter, welcome Flunixin Meglumine Injection, Flunixin Meglumine Paste, Flunixin Meglumine For Animal purchasers from worldwide to visit our site.
Looking for antimoniate? Find out information about antimoniate. The radical - in salts derived from antimony pentoxide, Sb4O10, and bases. McGraw-Hill Dictionary of Scientific & Technical Terms, 6E, Copyright © 2003 by... Explanation of antimoniate
Gadopentetate dimeglumine (also known as MagnevistTM) is an extracellular intravenous contrast agent used in magnetic resonance imaging. linear, ionic molecule 100% renally excreted T1 relaxivity @ 1.5 T: 3.9-4.3 concentration: 0.5 mmol/mL ...
Cutaneous leishmaniasis is an endemic disease in Iran and there is no curative treatment. The disfiguring scar that remains after it subsidesis a major psychologic and emotional problem in these patients. Chronic leishmaniasisis a rare form of this malady which is seen in 5-7 percent of cases. In this article we report a 46-year-old man who was refered to us for a large leishmaniasis lesion consisting of a scaling erythematous plaque with several papules on the right side of face and nose. This patient was treated by a combination of systemic Glucantime, 50% trichlroacetic acid and oral fluconazole. Complete resolution was achieved after 4 ...
Twenty-two patients (64 ± 10.2 years) with suspected coronary artery disease underwent cardiac MR examination at 3 T (MAGNETOM Tim Trio, Siemens, Germany) after informed consent was obtained. Coronary arteries were imaged using an ECG-triggered, navigator-gated, inversion-recovery, segmented gradient-echo sequence with isotropic whole-heart coverage. A twelve-element matrix coil (six anterior and six posterior) was used for data acquisition. To speed up data acquisition, parallel acquisition (GRAPPA) was used in the phase-encoding direction with an acceleration factor of two. Imaging parameters included: voxel size 0.65 × 0.65 × 0.65 mm3 (interpolated from 1.3 × 1.3 × 1.3 mm3), TR/TE = 3.3/1.5 msec, flip angle = 20°, bandwidth = 700 Hz/pixel, imaging time = 8.8 ± 1.9 min. Contrast agent (0.2 mmol/kg body weight, Multihance, Bracco Imaging SpA, Italy) was intravenously administered at the rate of 0.3 ml/sec using a Medrad power injector. All patients received x-ray angiography (CAG) within ...
Buy Vetameg (flunixin meglumine) Injectable for Horses & Livestock, 50 mg/mL,100-mL vial at Chewy.com. FREE shipping and the BEST customer service!
TY - JOUR. T1 - Arterial visualization by contrast-enhanced moving-table MR angiography. T2 - Crossover comparison of 0.1 and 0.2 mmol/kg doses of meglumine gadopentetate in normal volunteers. AU - Hayashi, Hiromitsu. AU - Yuasa, Yuji. AU - Amano, Yasuo. AU - Tanimoto, Akihiro. AU - Saito, Yoko. AU - Yoshioka, Kunihiro. AU - Kita, Miho. AU - Kumazaki, Tatsuo. AU - Hiramatsu, Kyoichi. PY - 2008/9/1. Y1 - 2008/9/1. N2 - Purpose: To determine the appropriate dose of contrast medium for moving-table MR angiography (MT-MRA) from the abdominal aorta to the ankle by comparing visualization with different doses of meglumine gadopentetate (Gd-DTPA) administered in crossover fashion to normal volunteers. Materials and Methods: Twelve healthy adults underwent imaging after crossover administration of 0.1 and 0.2 mmol/kg of Gd-DTPA in random order. Continuous MT-MRA was performed with a fast 3D spoiled gradient echo sequence without parallel imaging technique. Visualization was evaluated in a total of 252 ...
RESULTS Considering the whole group of MR examinations performed either without (n = 26) or without and with intravenous injection of gadopentetate dimeglumine (n = 16), overall 20 MR studies were judged to show disease. Seventeen of 26 microadenomas were adequately shown and located by MR (true-positive, 65.4%). In three cases the sides of the microadenomas were misjudged (false-positive, 11.5%). Six patients had negative MR studies (false-negative, 23%). Twelve of the 16 patients studied after gadopentetate dimeglumine injection had true-positive MR findings (75%).. ...
Potassium antimonate trihydrate, >94%, Alfa Aesar™ 50g Potassium antimonate trihydrate, >94%, Alfa Aesar™ Inorganic Potassium Compounds
PURPOSE: To investigate for the first time the feasibility of aortic four-dimensional (4D) flow at 7T, both contrast enhanced (CE) and non-CE. To quantify the signal-to-noise ratio (SNR) in aortic 4D flow as a function of field strength and CE with gadobenate dimeglumine (MultiHance). METHODS: Six healthy male volunteers were scanned at 1.5T, 3T, and 7T with both non-CE and CE acquisitions. Temporal SNR was calculated. Flip angle optimization for CE 4D flow was carried out using Bloch simulations that were validated against in vivo measurements. RESULTS: The 7T provided 2.2 times the SNR of 3T while 3T provided 1.7 times the SNR of 1.5T in non-CE acquisitions in the descending aorta. The SNR gains achieved by CE were 1.8-fold at 1.5T, 1.7-fold at 3T, and 1.4-fold at 7T, respectively. CONCLUSION: The 7T provides a new tool to explore aortic 4D flow, yielding higher SNR that can be used to push the boundaries of acceleration and resolution. Field strength and contrast enhancement at all fields provide
Indomethacin,1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid,1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolylacetic acid,indometacin,Bonidon,Catlep,Chrono-Indocid,Confortid,Dolcidium,Elmetacin,Idomethine,Inacid,Indacin,Indocid,Indocin,Indomed,Indomee,Indomod,Indoptic,Indoptol,Indoxen,Inflazon,Inteban,Mikametan,Rheumacin LA,Serastar,Vonum,Sodium salt trihydrate,Indomethacin Sodium salt trihydrate,Indocin I.V.,Indocid PDA,Meglumine salt,Indomethacin, Meglumine salt,Liometacen
We recently discovered that induction from the anti-inflammatory gene by cyclic AMP occurs through book cyclic AMP-dependent proteins kinase-independent systems involving activation of CCAAT/enhancer-binding proteins (C/EBP) transcription elements, notably C/EBP, from the cyclic AMP GEF EPAC1 as well as the ...
Click to predict properties on the Chemicalize site, For medical information relating to Covid-19, please consult the, ACD/Labs Percepta Platform - PhysChem Module, Compounds with the same molecular formula, Search Google for structures with same skeleton. 435.73 g/mol. Article No. FDA UNII. IF SWALLOWED: Call a POISON CENTER or doctor/physician if you feel unwell. Linear Formula: KSb (OH)6. Tel: 1-800-343-0660 or 1-978-521-6300 Molecular Weight 262.89. Insoluble in ethanol. Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. , Match Criteria: CAS Number. Synonyms: Potassiumhexahydroxoantimonate(V), Potassium hexahydroxoantimonate, Potassium antimonate. H6KO6Sb-2. Synonyms: Potassium antimonate. Molecular Weight: 208.85 Molecular Formula: K.O3Sb Additional Metadata ... Additional Synonyms There are no Synonyms of this type. Description: Potassium hexahydroxoantimonate(V), Analytical, Purity: >/-99.0%, CAS ...
Hexabrix contrast agent is a low osmolar ionic dimer. Each milliliter contains 393 mg of ioxaglate meglumine, 196 mg of ioxaglate sodium and 0.10 mg of edetate calcium disodium as a stabilizer. The solution contains 3.48 mg ...
AccessGUDID - DR. POYNTER AMRC (30607915132973)- Kit Contains: CA090, DIRECT DRIVE® LCA 3/BX CTS02, 5x100 Kii® SLEEVE ZTHR 12/BX CTF33, 11x100 Kii® Fios® ZTHR 6/BX CTF03, 5x100 Kii® Fios® Z-THR 6/BX CD001, 10mm RETRIEVAL SYSTEM, 10/BX CB030, 5mmx35cm EPIX® LAPA SCISSOR, 10/BX
Meglumine diatrizoate + sodium diatrizoate is used in the treatment of .get complete information about meglumine diatrizoate + sodium diatrizoate including usage, side effects, drug interaction, expert advice along with medicines associated with meglumine diatrizoate + sodium diatrizoate at 1mg.com
The effect of flunixin meglumine and flurbiprofen on the course of experimental Escherichia coli mastitis was examined. Nine cows (within one month post partum) were inoculated intramammarily with 20 x 10(5) viable E coli in both rear quarters. Three cows remained untreated (controls); three cows received three injections of flunixin meglumine and three cows received flurbiprofen as two intravenous infusions. Flunixin meglumine and flurbiprofen were initially given before clinical signs were observed. Treatment was repeated if the cows temperature increased by more than 1 degree C. In the untreated cows, rectal temperature and heart rate increased from three hours after infection, and rumen motility (both frequency and amplitude) decreased from four hours after infection. Treatment with flunixin meglumine or flurbiprofen almost completely abolished the febrile response during the first nine hours after infection, and the decrease in rumen motility was less pronounced in the treated animals. ...
Parasites isolated from patients with non-healing lesions are frequently resistant to to meglumine antimoniate, the first line of treatment in Iran.
Differential Gene Expression across Breed and Sex in Commercial Pigs Administered Fenbendazole and Flunixin Meglumine. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
Flunixin meglumine is a non-steroidal anti-inflammatory medication used for treating inflammation and pain associated with musculoskeletal disease.
There are no laboratory studies available on bioaccumulation of antimony in earthworms. However, concentrations of antimony in soil and invertebrates at locations close to an antimony smelter have been measured by Ainsworth et al. (1990b). The highest antimony concentrations were found in earthworms (Oligochaeta). The dry weight concentrations (including gut contents) were 398 ± 94 mg/kg, 213 ± 65 mg/kg and 109 ± 28 mg/kg, at 100m, 250m and 450m downwind of the smelter. The EU RAR for diantimony trioxide used measurements presented in figures in Ainsworth et al.(1990b) to derive the following approximations for the 0-5, 5-10, 10-15 and ,15 cm depths for the 100m, 250m and 450m sites: 367, 253, 220 and 171 mg Sb/kg dw, 204, 155, 114 and 94 mg Sb/kg dw, and 180, 180, 163 and 135 mg Sb/kg dw, respectively. Ainsworth et al. gives earthworm body burden: soil ratios, which are 1.03, 1.05 and 0.6 for the 100m, 250m and 450m sites, respectively. Based on these data a biota-to-soil accumulation factor ...
Jinlan Pharm-Drugs Technology Co., Limited (with its export company Hangzhou Royall Import & Export Co.,Ltd.) is located in Hangzhou, Zhejiang Province. Neighboring Ningbo port, Shanghai port, Hangzhou Xiaoshan Intl Airport and Shanghai Pudong Intl Airport, the transportation and production environment are excellent. JINLAN PHARMA mainly business includes: 1) API, Pharmaceutical Intermediates, Custom Synthesis and so on. 2) Pharmaceutical Equipment such as: Distilled Water Machinery, Mixer, Sterilizer and so on. We are the biggest supplier for Contrast Agent in China such as: Iohexol, Iopromide, Ioversol, Iopamidol, Iodixanol, Iomeprol, Gadobenate Dimeglumine, Gadopentetate dimeglumine, Gadoteric acid, Gadodiamide, Caldiamide Sodium, and so on. JINLAN PHARMA focus on: Contrast Agent Vitamins API Pharmaceutical Intermediates Custom systhesis Contract manufacturing Our strongest Pharmaceutical Machines include: 1) Water Solution: Reverse Osmosis, Distilled Water Machine, Pure ...
Looking for online definition of chiclero's ulcer in the Medical Dictionary? chiclero's ulcer explanation free. What is chiclero's ulcer? Meaning of chiclero's ulcer medical term. What does chiclero's ulcer mean?
Yang Q, Li K, Liu X, Bi X, Liu Z, An J, Zhang A, Jerecic R, Li D. Contrast-enhanced whole-heart coronary magnetic resonance angiography at 3.0-T: a comparative study with X-ray angiography in a single center. J Am Coll Cardiol. 2009 Jun 30;54(1):69-76 ...
List of frequently occuring side effects for gastrografin. Sources include the official FAERS database and social media including user reviews and forum discussions.
New research published in the Nov. 21 issue of the Journal of the American College of Cardiology continues to advance the understanding of how whole-heart coronary MRI can be used to detect heart disease.. One drawback of heart MRIs is that clear images can be difficult to obtain. The hearts constant beating coupled with a patients constant breathing can blur images, rendering them unusable. Typically, images are collected during diastole. Researchers at Mie University Hospital and Matsusaka Central Hospital in Japan investigated whether image data should be collected at other times.. Researchers used whole-heart MRIs on 131 patients suspected of having coronary artery stenosis. In 48 patients, especially those with faster heart rates, the optimal time to collect data occurred while the heart was contracting rather than resting. Overall, useable images were collected in 113 patients, or 86 percent of the study participants. The study found that, for coronary arteries of at least 2 mm in ...
Bianca ALWAYS needs volunteers. The number of animals we take care of is enormous and they need treatment and walking so that they wouldnt get restless.. So, even if you have only one hour a week available, come to us and you will see that it will be rewarding. We need you to give them the help they deserve. Please show up !. ...
We use Google Ads to increase awareness for our company and to market our products. There is no advertising or marketing content from third parties on this website ...
"Baxdela- delafloxacin meglumine tablet Baxdela- delafloxacin meglumine injection, powder, lyophilized, for solution". DailyMed ... "Delafloxacin meglumine". Drug Information Portal. U.S. National Library of Medicine. Medicine portal. ... The injectable form of delafloxacin is sold as the meglumine salt of the active ingredient and its United States Adopted Name, ... delafloxacin meglumine, reflects that; the injection formulation also includes EDTA and sulfobutylether-β-cyclodextrin. The ...
"Tafamidis meglumine Orphan Drug Designation and Approval". U.S. Food and Drug Administration (FDA). 3 May 2019. Archived from ... It is marketed as a meglumine salt. It is slightly soluble in water. The laboratory of Jeffery W. Kelly at The Scripps Research ... "Tafamidis meglumine". Drug Information Portal. U.S. National Library of Medicine. Medicine portal. ... The FDA approved tafamidis meglumine based primarily on evidence from a clinical trial (NCT01994889) of 441 adult patients. The ...
meglumine antimoniate (Glucantim; manufactured by Aventis; available in Brazil, France and Italy), which is administered by ...
... and is used in form of the meglumine salt (gadoterate meglumine). The paramagnetic property of gadoteric acid reduces the T1 ... The meglumine salt it takes the form of crosses the blood brain barrier of tissue with abnormal vasculature, highlighting the ... In 2017, GE Healthcare launched a gadoteric acid (as gadoterate meglumine) under the trade name Clariscan Other FDA approved ... "US gadoterate meglumine label" (PDF). FDA. March 2013. DrugBank, ed. (2016-08-22). "Gadoteric acid". DrugBank. Todd DJ, Kay J ( ...
It was applied in form of its salt, meglumine iocarmate. It is not known to be marketed anywhere in the world in 2021. Schütte ... Van Dellen JR, Lipschitz R (October 1973). "Meglumine iocarmate (Dimer-X) ventriculography". Clinical Radiology. 24 (4): 449-52 ...
MEGLUMINE IOCARMATE 306. MELAGENINA 307. MELITRACEN HYDROCHLORIDE 308. MELOXICAM 309. MEPHENESIN, ITS ESTERS ...
"Vyndaqel (tafamidis meglumine) NDA 202737" (PDF). U.S. Food and Drug Administration Center for Drug Evaluation and Research ...
This may include intravenous fluids and electrolytes to counteract the diarrhea; NSAIDs such as Banamine (flunixin meglumine); ...
Amersham Health (April 2006). "Hypaque (Diatrizoate Meglumine and Diatrizoate Sodium) injection, solution. Product label". ...
... meglumine Flunixin Meglumine For Veterinary Use Flunixin licensing in the UK provided by Norbrook. ... It is often formulated as the meglumine salt. In the United States, it is regulated by the U.S. Food and Drug Administration ( ... Soma LR, Behrend E, Rudy J, Sweeney RW (November 1988). "Disposition and excretion of flunixin meglumine in horses". American ... Bryant CE, Farnfield BA, Janicke HJ (February 2003). "Evaluation of the ability of carprofen and flunixin meglumine to inhibit ...
... and as the meglumine salt for intravenous administration, which has the generic name estramustine phosphate meglumine. The INNM ... EMP is provided as the sodium or meglumine salt. EMP is similar as a compound to other estradiol esters such as estradiol ...
Flunixin meglumine (Banamine) may help block the effects of toxemia. Mortality rate has been theorized to fall to 75% if ...
She has also worked with dengue diagnosis in Colombia, and participated in clinical trials evaluating the use of meglumine ... Castro MD, Cossio A, Velasco C, Osorio L (April 2017). "Risk factors for therapeutic failure to meglumine antimoniate and ... February 2012). "Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children". The ...
... flunixin meglumine, and ketoprofen in horses". Journal of the American Veterinary Medical Association. 202 (1): 71-7. PMID ...
1993) Effects of large doses of phenylbutazone, flunixin meglumine, and ketoprofen in horses. J. Am. Vet. Med. Ass. 202, 71-77 ... Foreman, J. H.; Ruemmler, R. (2011). "Phenylbutazone and flunixin meglumine used singly or in combination in experimental ... although flunixin meglumine and firocoxib are also commonly used for orthopedic pain. Despite their widespread use, NSAIDs do ...
It is available in form of its salts, sodium iotalamate and meglumine iotalamate. It can be given intravenously or ...
It is applied in form of its salts, ioxaglate meglumine and ioxaglate sodium. Uses include angiography (imaging of blood ...
It is used in form of its salts, ioxitalamate sodium and ioxitalamate meglumine. Wiggli U (January 1979). "[Clinical study of ...
Taenzer V, Volkhardt V (January 1979). "Double blind comparison of meglumine iotroxate (Biliscopin), meglumine iodoxamate ( ... Endobil), and meglumine ioglycamate (Biligram)". AJR. American Journal of Roentgenology. 132 (1): 55-8. doi:10.2214/ajr.132.1. ...
"The analgesic effect of ketoprofen for use in treating equine colic as compared to flunixin meglumine". Equine Pract. 13: 11-16 ...
To do an IVC, an iodine-containing dye (meglumine ioglycamate) is injected intravenously into the blood. The liver then removes ...
Coble, D.J., Taylor, D.K. and Mook, D.M. (2011). "Analgesic effects of meloxicam, morphine sulfate, flunixin meglumine, and ...
... when cation A is the protonated form of the amino sugar meglumine the salt goes under the name "gadopentetate dimeglumine". It ...
Anti-inflammatory therapy is usually given both systemically, often in the form of flunixin meglumine, and topically, as ...
... -based drugs, such as meglumine antimoniate, are also considered the drugs of choice for treatment of leishmaniasis in ...
After the introduction of antimony(V) containing complexes like sodium stibogluconate and meglumine antimoniate, the use of ...
... (trade name Biliscopin), used in the form of meglumine iotroxate, is a molecule used as a contrast medium during ...
... launched a macrocyclic extracellular gadolinium based contrast agent containing gadoteric acid as gadoterate meglumine under ...
FDA Reminds Veterinarians on the Correct Use of Flunixin Meglumine May 15, 2007 U.S. Food and Drug Administration, Center for ...
Pentavalent antimonial drugs (sodium stibogluconante [SSG] and meglumine antimonite [Glucantime, MA]) have been used since the ...
... iothalamate meglumine and iodipamide meglumine. Flunixin meglumine Meglumine antimoniate Meglumine, chemicalland21.com v t e v ... Meglumine is an amino sugar derived from glucose. It is often used as an excipient in pharmaceuticals and in conjunction with ... iodinated compounds in contrast media such as diatrizoate meglumine, ...
Meglumine antimoniate came into medical use in 1946. It is on the World Health Organizations List of Essential Medicines. It ... Meglumine World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health ... in German) "Meglumine antimoniate". Drug Information Portal. U.S. National Library of Medicine. Medicine portal. ... Meglumine antimoniate is a medicine used to treat leishmaniasis. This includes visceral, mucocutaneous, and cutaneous ...
If you have an allergy to diatrizoate meglumine or any other part of this drug. ...
Delafloxacin Meglumine reference guide for safe and effective use from the American Society of Health-System Pharmacists (AHFS ... Delafloxacin meglumine is a fluoroquinolone anti-infective agent.1. Uses for Delafloxacin Meglumine. Delafloxacin meglumine has ... Delafloxacin Meglumine Dosage and Administration. General. Delafloxacin meglumine is available in the following dosage form(s) ... Discontinue delafloxacin meglumine immediately and avoid the use of fluoroquinolones, including delafloxacin meglumine, in ...
Read the side effects of Gadoterate meglumine as described in the medical literature. In case of any doubt consult your doctor ... Side effect(s) of Gadoterate meglumine Read the side effects of Gadoterate meglumine as described in the medical literature. In ... Gadoterate meglumine - Information. Gadoterate meglumine is a gadolinium based contrast agent, prescribed for visualization of ...
DOTAREM- gadoterate meglumine injection. To receive this label RSS feed. Copy the URL below and paste it into your RSS Reader ... DOTAREM- gadoterate meglumine injection. Out of scope - Out of scope for RxNorm and will not receive RxNorm normal forms. Out ... Gadoterate meglumine was administered in intravenous doses of 0, 2, 4 and 10 mmol/kg/day [3, 7 and 16 times the recommended ... gadoterate meglumine (UNII: L0ND3981AG) (GADOLINIUM CATION (3+) - UNII:AZV954TZ9N) GADOLINIUM CATION (3+). 376.9 mg in 1 mL. ...
Learn about the potential side effects of gadoterate meglumine. Includes common and rare side effects information for consumers ... Applies to gadoterate meglumine: intravenous solution. Along with its needed effects, gadoterate meglumine may cause some ... Check with your doctor or nurse immediately if any of the following side effects occur while taking gadoterate meglumine:. Rare ... Some side effects of gadoterate meglumine may occur that usually do not need medical attention. These side effects may go away ...
Although there is no specific information comparing use of meglumine antimoniate in children with use in other age groups, this ... There is no specific information comparing use of meglumine antimoniate in the elderly with use in other age groups. ...
Ioxaglate Meglumine and Ioxaglate Sodium Adult Medication. *. ... Ioxaglate Meglumine and Ioxaglate Sodium. ©2018 Memorial Sloan ...
Flunixin Meglumine Doses: More or Less? (AAEP 2012). *By Nancy S. Loving, DVM ... In this study the scientists compared the effects of varying intravenous doses (half-dose, 1x, 2x) of flunixin meglumine; they ... Plasma concentrations of flunixin meglumine increased in a dose-dependent manner, but by Hour 8, there was no difference among ... This is significant when treating colicking horses with smaller doses of flunixin meglumine to alleviate intestinal pain and ...
Flunixin meglumine is a non-steroidal anti-inflammatory medication used for treating inflammation and pain associated with ... Flunixin meglumine is a non-steroidal anti-inflammatory medication used for treating inflammation and pain associated with ...
Gadoterate meglumine is used to help diagnose certain disorders of the brain and spine... ... Gadoterate meglumine is a contrast agent that has magnetic properties. It is used in combination with magnetic resonance ... How is gadoterate meglumine given?. Gadoterate meglumine is given as an infusion into a vein. A healthcare provider will give ... What is gadoterate meglumine?. Gadoterate meglumine is a contrast agent that has magnetic properties. It is used in combination ...
Gadoterate meglumine(Dotatrem) generic is a gadolinium based contrast agent, prescribed for visualization of brain along with ... Generic Name : Gadoterate meglumine Latest prescription information about Gadoterate meglumine. Learn how to pronounce the ... How should Gadoterate meglumine be taken? It comes as a powder for injection (diluted with fluid) to be administered by a ... What are the side effects of Gadoterate meglumine? Most frequent: Nausea, headache, injection site pain, injection site ...
Meglumine: 1-Deoxy-1-(methylamino)-D-glucitol. A derivative of sorbitol in which the hydroxyl group in position 1 is replaced ... Meglumine. Subscribe to New Research on Meglumine 1-Deoxy-1-(methylamino)-D-glucitol. A derivative of sorbitol in which the ... and the result of treatment with meglumine antimonate. ". 04/01/1997 - "Primary and secondary unresponsiveness to meglumine has ... 09/01/1992 - "Pentavalent antimony in the form of meglumine antimonate had an SD (84) of 416 mg/kg. In a second experiment in ...
We do not have alternatives for Meglumine Gadobenate since it is relatively safe. ...
Meglumine lodipamide (Cholografin®) Hepatotoxicity L. R. SUTHERLAND, M.D.; L. A. EDWARDS, M.D., F.R.C.P.(C); A. MEDLINE, M.D., ... Two cases of meglumine iodipamide (Cholografin®) hepatotoxicity were confirmed by liver biopsy. The hepatic lesion was ... Meglumine lodipamide (Cholografin®) Hepatotoxicity. Ann Intern Med. 1977;86:437-439. doi: https://doi.org/10.7326/0003-4819-86- ...
GE Healthcares Clariscan™ (gadoterate meglumine) Becomes Only FDA-Approved MRI Contrast Agent Available in Polymer Bottle * US ... Additional pediatric use information is approved for Guerbet LLCs Dotarem (gadoterate meglumine injection). However, due to ... Pediatric use: The safety and efficacy of gadoterate meglumine at a single dose of 0.1 mmol/kg has been established in ... CLARISCAN™ (gadoterate meglumine) is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance ...
A multinational study of more than 35,000 patients who had a MRI scan with gadoterate meglumine has verified that it is a well- ... A multinational study of more than 35,000 patients who had a MRI scan with gadoterate meglumine has verified that it is a well- ... Gadoterate meglumine is a macrocyclic paramagnetic GBCA with high thermodynamic stability. First used in Europe in 1989, it has ... Observational Study on the Safety Profile of Gadoterate Meglumine in 35,499 Patients: The SECURE Study. J Magn Reson Imaging. ...
... induced by parenteral meglumine antimoniate (Glucantime) in a 40-year-old man who traveled to Bolivia and was treated for ... f Drug Hypersensitivity Syndrome Induced by Meglumine Antimoniate * Fakhri Jeddi1,*, Eric Caumes1, Marc Thellier1, Stéphane ... Acute pancreatitis caused by meglumine antimoniate given for the treatment of visceral leishmaniasis. Rev Soc Bras Med Trop 37 ... Drug Hypersensitivity Syndrome Induced by Meglumine Antimoniate. The American Journal of Tropical Medicine and Hygiene 80, 939 ...
Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis. The safety ... Meglumine antimoniate. Bronchodilator Agents. Autonomic Agents. Peripheral Nervous System Agents. Physiological Effects of ... During 20 days Group 1 will receive simultaneously meglumine antimoniate and placebo of nitric oxide patches while Group 2 will ... to Evaluate the Effectiveness of a Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of ...
The fact that meglumine antimoniate has caused important changes in mice tissues, with relevant toxic effects in both heart and ... Meglumine antimoniate in the cortex (F). Cerebellum of mice treated with oxiranes showed degeneration in Purkinje neurons (H, I ... Meglumine antimoniate showed the lowest values for oral and intestinal absorption as was already known. However, all these ... As expected, meglumine antimoniate induced severe changes in heart tissue and curiously caused changes to the lung tissue ( ...
Flunixin meglumine was administered at an actual mean dose of 2.21mg per kg (range: 2.05-2.48mg per kg) IV, IM and PO. ... In their study, six mature swine (121-168kg) were administered an IV, IM or PO dose of flunixin meglumine at a target dose of ... Pharmacokinetics of Flunixin Meglumine in Mature Swine after Intravenous, Intramuscular and Oral Administration. Disease and ... Pharmacokinetics of flunixin meglumine in mature swine after intravenous, intramuscular and oral administration. BMC Veterinary ...
Diatrizoate meglumine) drug information & product resources from MPR including dosage information, educational materials, & ... Diatrizoate meglumine 180mg/mL; soln for inj; contains organically bound iodine 85mg/mL. ...
Flunazine Flunixin Meglumine Solution Bimeda Safe.Pharmacy,Inflammation and Pain , Livestock Rx , ... Flunazine is a nonsteroidal anti-inflammatory drug (NSAID). Each ml of Flunazine contains flunixin meglumine equivalent to 50 ...
Banamine (Flunixin Meglumine) Veterinary is rated 4.90 out of 5 by 42. ... Each ml of Banamine Injectable Solution contains flunixin meglumine equivalent to 50 mg flunixin. ...
Treatment cycles were repeated monthly to a maximum of 4 months; 27 patients received 60 mg/kg intramuscular meglumine ... f Efficacy of Azithromycin versus Systemic Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis * ... Treatment cycles were repeated monthly to a maximum of 4 months; 27 patients received 60 mg/kg intramuscular meglumine ... Efficacy of Azithromycin versus Systemic Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis ...
Iothalamate meglumine) drug information & product resources from MPR including dosage information, educational materials, & ... Iothalamate meglumine 600mg/mL; soln for IV infusion; organically bound iodine 282mg/mL. ...
Comparison of Gadoterate Meglumine and Gadobutrol in the MRI Diagnosis of Primary Brain Tumors: A Double-Blind Randomized ... Comparison of Gadoterate Meglumine and Gadobutrol in the MRI Diagnosis of Primary Brain Tumors: A Double-Blind Randomized ... Comparison of Gadoterate Meglumine and Gadobutrol in the MRI Diagnosis of Primary Brain Tumors: A Double-Blind Randomized ... Comparison of Gadoterate Meglumine and Gadobutrol in the MRI Diagnosis of Primary Brain Tumors: A Double-Blind Randomized ...
Afterwards, each of the two lesions of the patient was treated by one of the two following treatments: 1500 mg/5 µl Meglumine ... The effect of Nd:YAG laser therapy on cutaneous leishmaniasis compared to intralesional meglumine antimoniate. Mohammad Omidian ... Radmanesh M, Omidian E. The pulsed dye laser is more effective and rapidly acting than intralesional meglumine antimoniate ... They also treated another group of 95 patients with intralesional injections of the Meglumine Antimonite and cryotherapy for 12 ...
Find details on Flunixin meglumine. Medication for cats including uses, administration, pharmacokinetics, precautions, adverse ... The use of flunixin meglumine in small animal medicine has declined since the introduction of other NSAIDs with higher ...
  • We report a case of drug hypersensitivity syndrome (drug reaction with eosinophilia and systemic symptoms [DRESS]) induced by parenteral meglumine antimoniate (Glucantime) in a 40-year-old man who traveled to Bolivia and was treated for mucocutaneous leishmaniasis. (ajtmh.org)
  • Pentavalent antimony compounds such as Glucantime (Meglumine antimoniate) are the first-line treatment of leishmaniasis. (termedia.pl)
  • This study identified the infecting Leishmania species and evaluated the results of meglumine antimoniate (Glucantime®) therapy in a new focus of cutaneous leishmaniasis in Birjand, eastern Islamic Republic of Iran. (who.int)
  • 81 dogs naturally infected with Leishmania infantum in the Isle of Elba, Italy, were treated with meglumine antimoniate (Glucantime). (nih.gov)
  • In this case control study, the therapeutic effect of Thio- Ben ( combination of thioxolon and benzoxonium chloride) was compared to intralesional meglumine antymoniate ( glucantime) treatment. (ac.ir)
  • For Injection: 300 mg of delafloxacin (equivalent to 433 mg delafloxacin meglumine) as a lyophilized powder in a single-dose vial for reconstitution and further dilution before intravenous infusion. (drugs.com)
  • DOTAREM Injection 0.5 mmol/mL contains 376.9 mg/mL of gadoterate meglumine and is available in vials and pre-filled syringes. (nih.gov)
  • Some side effects of gadoterate meglumine may occur up to several days after injection. (wellspan.org)
  • Ioxaglate Meglumine and Ioxaglate Sodium Injection is a sterile solution of Ioxaglic Acid in Water for Injection, prepared with the aid of Meglumine and Sodium Hydroxide. (drugfuture.com)
  • Ioxaglate Meglumine and Ioxaglate Sodium Injection intended for intravascular use contains no antimicrobial agents. (drugfuture.com)
  • Evaporate a volume of Injection, equivalent to about 500 mg of ioxaglate meglumine and ioxaglate sodium, to dryness, and heat the residue so obtained in a crucible: violet vapors are evolved. (drugfuture.com)
  • Test solution Transfer a volume of Injection, equivalent to a total of 1.0 g of ioxaglate meglumine and ioxaglate sodium, to a 50-mL color-comparison tube, and dilute with water to 5 mL. (drugfuture.com)
  • Test solution Transfer a volume of Injection, equivalent to 2 g of the total of ioxaglate meglumine and ioxaglate sodium, to a 50-mL centrifuge tube, add 25 mL of water and 15 mL of 2 N sulfuric acid, and mix thoroughly. (drugfuture.com)
  • Assay for iodine Transfer an accurately measured volume of Injection, equivalent to about 5 g (total) of ioxaglate meglumine and ioxaglate sodium, to a 250-mL volumetric flask, dilute with water to volume, and mix. (drugfuture.com)
  • Five cattle in each group received three doses of flunixin meglumine administered by either intravenous infusion or intramuscular injection at 24 h intervals. (elsevier.com)
  • NAME: Flunixin Meglumine Injection COMPOSITION: 50ml: 2.5g flunixin as meglumine 50mg per ml. (ncpcvet.com)
  • iothalamate meglumine injection is a topic covered in the Taber's Medical Dictionary . (unboundmedicine.com)
  • Nursing Central Redesign , nursing.unboundmedicine.com/nursingcentral/view/Tabers-Dictionary/729575/all/iothalamate_meglumine_injection. (unboundmedicine.com)
  • Function Antipyretic Analgesics Dosage Form Injection Animal Type Cattle, Fowl, Horse, Other Special Breeding Animals, Pets, Pig, Sheep Place of Origin Sichuan, China (Mainland) Brand Name Chengkang Model Number 10ml/vial Appearance Colorless to slight yellow transparent liquid Composition Flunixin meglumine Specification 10ml Original Sichuan, China Sample Available MOQ 1 Carton Certificate GMP OEM Accept Product Description Flunixin Meglumine Injection Main C. (jiulonghxyy.com)
  • Product categories of Flunixin Meglumine , we are specialized manufacturers from China, Flunixin Injection , Flunixin Meglumine Injection suppliers/factory, wholesale high-quality products of Flunixin Meglumine Paste R & D and manufacturing, we have the perfect after-sales service and technical support. (kexingpharma.com)
  • Flunixin Meglumine 10% Injection Flunixin meglumine Injection 10% is a relatively potent non-narcotic, non-steroidal analgesic with anti-inflammatory and anti-pyretic properties. (kexingpharma.com)
  • Analysis errors can occur in the desorbing process of ginkgo diterpene lactone meglumine injection (GDMI) by a conventional analysis method , due to several factors, such as easily crystallized samples, solvent volatility , time -consuming sample pre-processing, fixed method , and offline analysis . (bvsalud.org)
  • Additional pediatric use information is approved for Guerbet LLC's Dotarem (gadoterate meglumine injection). (genewsroom.com)
  • In the U.S., Guerbet markets Optimark® (gadoversetamide) injection and Dotarem® (gadoterate meglumine) injection. (prnewswire.com)
  • Comparison between topical treatment with thioxolone , benzoxonium chloride tincture and intralesional injection of meglumine antymoniate on cutaneous leishmaniasis', Journal of Kerman University of Medical Sciences , 2(1), pp. 7-14. (ac.ir)
  • Serological and parasitological follow-up in dogs experimentally infected with Leishmania infantum and treated with meglumine antimoniate. (semanticscholar.org)
  • Gadoterate meglumine is a gadolinium based contrast agent, prescribed for visualization of brain along with with magnetic resonance imaging (MRI). (medindia.net)
  • CLARISCAN™ (gadoterate meglumine) is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine, and associated tissues in adult and pediatric patients to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity. (businesswire.com)
  • A multinational study of more than 35,000 patients who had a MRI scan with gadoterate meglumine has verified that it is a well-tolerated gadolinium-based contrast agent (GBCA) and has an excellent safety profile. (appliedradiology.com)
  • The purpose of this study is to determine whether adding pentoxifylline to treatment of American cutaneous leishmaniasis with meglumine antimoniate increases the rate and speed of clinical response without diminishing safety, and to identify immune correlates of the healing response. (clinicaltrials.gov)
  • This study will evaluate the efficacy and safety of using pentoxifylline (PTX) as a co-adjuvant in the treatment of cutaneous leishmaniasis with meglumine antimoniate in a randomized, double-blind, controlled trial. (clinicaltrials.gov)
  • Read the side effects of Gadoterate meglumine as described in the medical literature. (medindia.net)
  • Some side effects of gadoterate meglumine may occur that usually do not need medical attention. (drugs.com)
  • Some side effects of gadoterate meglumine may not be reported. (drugs.com)
  • What are the possible side effects of gadoterate meglumine? (wellspan.org)
  • The study's objectives were to prospectively investigate the safety of gadoterate meglumine (Dotarem® or Magnescope®, Guerbet, Roissy-Charles de Gaulle, France) in observational conditions and to assess the overall incidence of nephrogenic systemic fibrosis (NSF) in patients with renal impairment. (appliedradiology.com)
  • The researchers conclude from their results that PO administration of flunixin meglumine is not the most effective route for mature swine when compared to IV and IM. (thepigsite.com)
  • Purpose: To determine the appropriate dose of contrast medium for moving-table MR angiography (MT-MRA) from the abdominal aorta to the ankle by comparing visualization with different doses of meglumine gadopentetate (Gd-DTPA) administered in crossover fashion to normal volunteers. (elsevier.com)
  • Here, we evaluated the long-term efficacy of treatment with meglumine antimoniate plus allopurinol (G1) compared to miltefosine plus allopurinol (G2) in dogs naturally infected L. infantum . (biomedcentral.com)
  • ABSTRACT In order to define the protein expressional changes related to the process of meglumine antimoniate resistance in anthroponotic cutaneous leishmaniasis (CL), we performed a comparative proteomics analysis on sensitive and resistant strains of Leishmania tropica isolated from Iranian CL patients. (who.int)
  • Resistance of Leishmania (Viannia) Panamensis to Meglumine Antimoniate or Miltefosine Modulates Neutrophil Effector Functions. (unil.ch)
  • The most commonly used treatments for CanL are a combination of meglumine antimoniate plus allopurinol, or miltefosine plus allopurinol. (biomedcentral.com)
  • One arm will receive meglumine antimoniate and PTX and the other arm will receive meglumine antimoniate plus placebo. (clinicaltrials.gov)
  • It is often used as an excipient in pharmaceuticals and in conjunction with iodinated compounds in contrast media such as diatrizoate meglumine, iothalamate meglumine and iodipamide meglumine. (wikipedia.org)
  • It is often used as an excipient in pharmaceuticals and in conjunction with iodinated compounds in contrast media such as diatrizoate meglumine and iodipamide meglumine. (meddic.jp)
  • 27 patients received 60 mg/kg intramuscular meglumine antimoniate for 20 days. (ajtmh.org)
  • Meglumine is an amino sugar derived from glucose. (wikipedia.org)
  • The facility, validated by the FDA, is the only location in Europe that manufactures meglumine, an amino sugar derived from glucose. (emdgroup.com)
  • three cows received three injections of flunixin meglumine and three cows received flurbiprofen as two intravenous infusions. (bmj.com)
  • The generic name of Cysto-conray Ii is iothalamate meglumine. (ndclist.com)
  • Buy 6 Banamine (Flunixin Meglumine) Veterinary (item 134RX) and save! (valleyvet.com)
  • It contains not less than 95.0 percent and not more than 105.0 percent of the labeled amounts of ioxaglate meglumine (C 24 H 21 I 6 N 5 O 8 ·C 7 H 17 NO 5 ) and iodine (I). It may contain small amounts of Edetate Calcium Disodium as a stabilizer. (drugfuture.com)
  • Plasma concentrations of flunixin meglumine increased in a dose-dependent manner, but by Hour 8, there was no difference among concentrations at half-dose, 1x, and 2x doses. (bloodhorse.com)
  • Principal investigator Professor Philippe Soyer, MD, PhD, head of the Department of Body and Interventional Imaging and chairman of the radiology department at Hôpital Lariboisière in Paris, and co-authors reported that there was no statistically significant difference between patients with and without adverse drug reactions according to gender, age, body mass index (BMI), mean volume, or mean dose of gadoterate meglumine injected. (appliedradiology.com)
  • In their study, six mature swine (121-168kg) were administered an IV, IM or PO dose of flunixin meglumine at a target dose of 2.2mg per kg in a cross-over design with a 10-day wash-out period between treatments. (thepigsite.com)
  • Flunixin meglumine was administered at an actual mean dose of 2.21mg per kg (range: 2.05-2.48mg per kg) IV, IM and PO. (thepigsite.com)
  • After a single oral dose of tafamidis meglumine 20 mg, approximately 59% of the dose was recovered in feces (mostly as the unchanged drug) and approximately 22% of the dose was recovered in urine (mostly as the glucuronide metabolite). (com.sv)
  • Six mature swine (121-168 kg) were administered an IV, IM, or PO dose of flunixin meglumine at a target dose of 2.2 mg/kg in a cross-over design with a 10 day washout period between treatments. (beds.ac.uk)
  • Flunixin meglumine was administered at an actual mean dose of 2.21 mg/kg (range: 2.05-2.48 mg/kg) IV, IM and PO. (beds.ac.uk)
  • Tafamidis meglumine (Fx-1006A) is a potent and selective transthyretin (TTR) stabilizer, shows comparable potency and efficacy to the mutumant homotetramers V30M-TTR, V122I-TTR and wild type WT-TTR, with EC 50 s of 2.7-3.2 μM. (medchemexpress.com)
  • Long-term, the clinical and laboratory findings of the G1 dogs were more stable than those of the G2 dogs, thus indicating that meglumine antimoniate had better clinical efficacy than miltefosine. (biomedcentral.com)
  • A Pharmacokinetics, Efficacy, and Safety Study of Gadoterate Meglumine in Pediatric Subjects Aged Younger Than 2 Years. (unil.ch)
  • Researchers at Kansas State University and Iowa State University have collaborated to study the pharmacokinetics of the analgesic, flunixin meglumine, administered to mature pigs by the intravenous (IV), intramuscular (IM) and oral (PO) routes. (thepigsite.com)
  • What are the warnings and precautions for Gadoterate meglumine? (medindia.net)
  • Gadoterate meglumine is a contrast agent that has magnetic properties. (wellspan.org)
  • MARLBOROUGH, Mass.--( BUSINESS WIRE )--GE Healthcare's innovative shatterproof polymer + PLUS PAK Pharmacy Bulk Package has been approved by the US FDA for use with its macrocyclic gadolinium-based MRI contrast agent, Clariscan (gadoterate meglumine). (businesswire.com)
  • The meglumine salt form of diatrizoate, an organic, iodinated, radiopaque X-ray contrast medium used in diagnostic radiography. (semanticscholar.org)
  • Billerica, Massachusetts, January 17, 2017 - MilliporeSigma, a leading science and technology company, today announced the opening of a facility in Mollet des Vallès, Spain dedicated to the manufacture of meglumine, an FDA-approved excipient for pharmaceuticals and a component of medical imaging contrast media. (emdgroup.com)
  • Pentavalent antimony in the form of meglumine antimonate had an SD (84) of 416 mg/kg. (curehunter.com)
  • Discontinue delafloxacin meglumine immediately and avoid the use of fluoroquinolones, including delafloxacin meglumine, in patients who experience any of these serious adverse reactions. (drugs.com)
  • Avoid delafloxacin meglumine in patients with known history of myasthenia gravis. (drugs.com)
  • Delafloxacin meglumine is a fluoroquinolone anti-infective agent. (drugs.com)
  • Delafloxacin meglumine is a fluoroquinolone antibacterial indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria. (drugs.com)
  • To reduce the development of drug-resistant bacteria and maintain the effectiveness of delafloxacin meglumine and other antibacterial drugs, delafloxacin meglumine should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. (drugs.com)
  • Oral Tablets: 450 mg delafloxacin (equivalent to 649 mg delafloxacin meglumine). (drugs.com)
  • All intravenous doses of delafloxacin meglumine are administered over 60 minutes. (drugs.com)
  • Known hypersensitivity to delafloxacin meglumine or other fluoroquinolones. (drugs.com)
  • Discontinue delafloxacin meglumine immediately at the first signs or symptoms of any serious adverse reaction. (drugs.com)
  • In addition, avoid the use of fluoroquinolones, including delafloxacin meglumine, in patients who have experienced any of these serious adverse reactions associated with fluoroquinolones. (drugs.com)
  • Meglumine antimoniate is a medicine used to treat leishmaniasis. (wikipedia.org)
  • Systemic meglumine antimoniate (MA) therapy with 10-20 mg Sb5+/kg/day is the first choice of treatment. (figshare.com)
  • Meglumine Gadobenate and breastfeeding. (e-lactancia.org)
  • We do not have alternatives for Meglumine Gadobenate since it is relatively safe. (e-lactancia.org)
  • Acute pancreatitis caused by meglumine antimoniate given for the treatment of visceral leishmaniasis. (ajtmh.org)
  • Each ml of Flunazine contains flunixin meglumine equivalent to 50 mg flunixin. (valleyvet.com)
  • Other drugs may affect gadoterate meglumine, including prescription and over-the-counter medicines, vitamins, and herbal products. (wellspan.org)
  • Package leaflet: Infrmatin fr the user GASTROGRAFIN GASTROENTERAL SOLUTION Sdium amidtrizate and meglumine amidtrizate Read all f this leaflet carefully befre yu are given this medicine because it cntains imprtant infrmatin fr yu. (healthdocbox.com)
  • What should I avoid after receiving gadoterate meglumine? (wellspan.org)
  • Flunixin meglumine is a non-steroidal anti-inflammatory medication used for treating inflammation and pain associated with musculoskeletal disease. (vcahospitals.com)
  • Gadoterate meglumine may also be used for purposes not listed in this medication guide. (wellspan.org)
  • A US study suggests that intramuscular administration of the pain control medication, flunixin meglumine is more effective that the oral route. (thepigsite.com)
  • What other drugs will affect gadoterate meglumine? (wellspan.org)
  • The predicted pharmacokinetic properties and toxicological profiles of epoxy- α -lapachone and epoxymethoxy-lawsone have now been compared to those of meglumine antimoniate, and histological changes induced by these drugs in noninfected BALB/c mice tissues are described. (hindawi.com)
  • Flunixin meglumine should not be combined with other anti-inflammatory drugs that tend to cause ulcers, such as other NSAIDs and corticosteroids. (equimed.com)
  • You should not receive gadoterate meglumine if you are allergic to it. (wellspan.org)
  • What yu need t knw befre yu are given Gastrgrafin D nt use Gastrgrafin if yu are allergic t sdium amidtrizate, meglumine amidtrizate, idine r idinecntaining cntrast media r any f the ther ingredients f this medicine (listed in sectin 6) if yu have a cnditin caused by t much thyrid hrmne (manifest hyperthyridism). (healthdocbox.com)